Vanda Pharmaceuticals

Pharma

Vanda tests motion sickness drug Nereus in GLP-1 patients

Vanda is kicking off a phase 3 trial to evaluate the ability of its motion sickness drug Nereus to prevent vomiting in those taking a GLP-1 treatment.

Kevin Dunleavy Apr 9, 2026 2:56pm

Vanda secures long-awaited FDA hearing in jet lag approval bid

Mar 4, 2026 3:22pm

green light go go ahead advance yes streetlight

FDA signs off on Vanda's Bysanti for schizophrenia and bipolar I

Feb 23, 2026 11:35am

FDA rejects Vanda's Hetlioz for a 2nd time in jet lag disorder

Jan 8, 2026 11:20am

Vanda, Agios score holiday season FDA approvals

Jan 2, 2026 11:33am

Oak View Group Vanda Pharmaceuticals New York Islanders NHL sponsorship

Vanda inks a pair of sports sponsorship deals

Oct 8, 2025 11:36am